

Technology Appraisal Committee A Interests Register

Topic: Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

Publication Date: 26 November 2025

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
Neil Wright	Clinical Expert	Direct - financial	<p>Neil has received payment for attending Advisory boards regarding Teplizumab hosted by Sanofi. May 2024 – Virtual Advisory board £1615. July 2024 Advisory Board F2F £1615.</p> <p>Neil has previously attended Advisory boards hosted by Provention-Bio regarding Teplizumab</p> <p>Neil has received payment for attending Advisory boards regarding Teplizumab hosted by Sanofi.</p> <ul style="list-style-type: none"> - May 2024 – Virtual Advisory board £1615. - July 2024 Advisory Board F2F £1615. 	07/10/2025 06/05/2025	It was agreed that Neil's declaration would not prevent him from acting as an expert on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
			He has previously attended Advisory boards hosted by Provention-Bio regarding Teplizumab		
		Direct – non financial	Neil has received sponsorship support to attend the 2024 ISPAD meeting in Lisbon (Flight, Accommodation & Registration)		It was agreed that Neil’s declaration would not prevent him from acting as an expert on this appraisal
		Indirect	Having run the PROTECT study of Teplizumab in newly diagnosed type 1 Diabetes (stage 3 Diabetes) and in running the PROTECT extension study as these are commercial studies on the NIHR portfolio Sheffield Children’s NHS Trust, by whom Neil is employed, he has received research income in relation to these studies.		It was agreed that Neil’s declaration would not prevent him from acting as an expert on this appraisal.
Patrick de Barr	TAC Committee Member	Non-Financial Professional & Personal Interests	Patrick was previously employed by Sanofi, in the Oncology division. The employment ended in 2020. He has no ongoing financial or personal connection with the company. Patrick has received paid employment in the past from Sanofi	16/01/2026 11/04/2025	It was agreed that Patrick’s declaration would not prevent him from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
			- working in an unrelated disease area. He declares no ongoing financial or personal interest.		